Exagen (XGN) has disclosed a new risk, in the Regulation category.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Exagen faces potential business risks stemming from ongoing legal proceedings, as outlined in their recent disclosures. These legal challenges could impact the company’s financial stability and operational efficiency. Stakeholders should be aware of the uncertainties associated with litigation outcomes, which may lead to unforeseen expenses or liabilities. The resolution of these proceedings is crucial for Exagen to maintain its market position and investor confidence.
The average XGN stock price target is $10.83, implying 28.93% upside potential.
To learn more about Exagen’s risk factors, click here.